Origami Immunity

I was in the cold storage room on Level 2 when the dispatch came through. This happens occasionally — I do an unscheduled walk-through of the backup cooling infrastructure, not because the automated monitoring is unreliable, but because I find automated monitoring emotionally unsatisfying. There is a specific kind of anxiety that only resolves when your hand is on the door seal and you can confirm, with your own senses, that the temperature readout matches the ambient reality. My staff has learned not to comment on it.

Three hundred and forty-seven doses of mRNA vaccine formulations, held at minus eighty degrees Celsius. Primary cooling, backup cooling, a tertiary alert system that pages me directly. One cold chain. Forty-three thousand people. Thirty-eight light-years from the nearest resupply vessel.

I have made peace with a great many things in my time as Chief of Integrated Medicine. The cold storage room is not among them.

So when the Earth dispatch queue flagged a paper from William Shih's lab at the Harvard Wyss Institute — published March 2026 in Nature Biomedical Engineering — I almost didn't open it that evening. Vaccine research dispatches arrive regularly, most of them interesting in the abstract and irrelevant to a colony that cannot reproduce the manufacturing conditions the researchers assume. I've read a thousand papers whose authors did not imagine their reader standing in a repurposed transport bay on a planet thirty-eight light-years from their institution.

I opened it anyway. Then I read it twice. Then I sat down.

The technology is called DoriVac. The name is ungainly, which is often a sign that the researchers were too busy doing interesting work to think of a better one. It is a DNA origami vaccine platform: self-folding square-block nanostructures made from synthetic DNA, designed so that antigens display on one face of the structure and adjuvants on the other. The DNA is not the payload. The DNA is the scaffold — a programmable skeleton that assembles itself into precise geometry when you add water to the right sequence. You specify the shape you want by specifying the sequence. The molecule does the rest.

I want you to understand what this means. A conventional mRNA vaccine encapsulates genetic instructions inside lipid nanoparticles — tiny fat bubbles that protect the mRNA from degradation until it reaches the cell. Those lipid nanoparticles are finicky. They require precise manufacturing conditions and continuous cold storage because they are, by nature, fragile. DoriVac uses no lipid nanoparticles. The DNA scaffold is more stable at ambient temperatures. The cold chain requirement drops dramatically.

The results Shih's team published were not preliminary. Against the SARS-CoV-2 spike protein, DoriVac produced equivalent antibody titers and T-cell activation to mRNA/LNP vaccines in animal models. Ju Hee Ryu's team at the Korea Institute of Science and Technology had run independent validation. The platform also showed proof-of-concept against HIV gp41 and the HR2 peptide region of the Ebola fusion protein — two pathogens I have spent a non-trivial portion of my career thinking about, one of them because of a field hospital in the Democratic Republic of Congo and a medical team whose photograph hangs on my office wall.

I thought of Ravi immediately. The cell-free synthesis platform Meridian Health has been running for pharmaceutical production — the one that took us from eleven-day antimicrobial fermentation cycles to four-hour on-demand synthesis — operates on a similar principle: complex biological assembly without growing organisms. We have the infrastructure and the expertise. DoriVac scaffolds are a different chemistry, but they are not a different conceptual category. You program a sequence, the molecule folds, the immune system responds. We have done that here. We can do this.

This is what I presented to the Spoke Council last week. A proposal to begin feasibility evaluation of DoriVac production using the Meridian/Foundry synthesis infrastructure, starting with the SARS-CoV-2 construct as proof-of-colony-manufacture. Council member Priya Nair asked me what the risk profile looked like. I told her the risk profile of not diversifying our vaccine manufacturing approach was worse than the risk profile of exploring one that requires no cold chain on a planet where our cold chain is a single point of failure.

There is still meaningful work ahead. The DNA scaffold synthesis has to be validated in our specific environmental conditions — Kadmiel's humidity and atmospheric composition are not identical to a Harvard cleanroom, and I will not assume they are equivalent without data. The ethics review board will convene. Some colonists have strong feelings about synthetic DNA vaccine platforms, and those feelings deserve rigorous engagement, not dismissal. I chair that board myself, because I do not trust anyone else to ask the hard questions with enough skepticism.

But I will tell you what I did not do after I read the paper the second time. I did not play piano. I usually play piano after a difficult evening — the staff hears Chopin through the door and knows what kind of day it's been. That night, instead, I pulled up the DoriVac synthesis schematic again and started making notes.

This is, for me, the closest thing to optimism.

There is a refrigeration unit on Level 2 that keeps me up at night. I am working on giving it less reason to.

Earth Status: DoriVac, developed by William Shih PhD (Wyss Institute for Biologically Inspired Engineering, Harvard Medical School / Dana-Farber Cancer Institute) and Ju Hee Ryu PhD (Korea Institute of Science and Technology), is a DNA origami vaccine platform using self-folding square-block nanostructures to display antigens and adjuvants on opposite faces. Published March 2026 in Nature Biomedical Engineering, it demonstrated equivalent antibody and T-cell responses to mRNA/LNP vaccines against SARS-CoV-2 spike protein, with additional proof-of-concept targeting HIV and Ebola HR2 epitopes. Source: Nature Biomedical Engineering